AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2022 | $1,144,727 | Replaced |
| 2nd Quarter - Amendment (this page) | Jul 27, 2022 | $1,144,727 | Replaced |
| 2nd Quarter - Amendment | Jul 27, 2022 | $1,144,727 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
Medicare/Medicaid MMM
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
Budget/Appropriations BUD
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
Health Issues HCR
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
Disaster Planning/Emergencies DIS
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.